NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

JAZZ

Jazz Pharmaceuticals plc

Jun 30 • 04:00PM ET

106.12

Dollar change -0.78
Percentage change -0.73	%

Healthcare • Biotechnology • Ireland • NASD

Peers: VRTX REGN BIIB INCY GILD BMRN NBIX EXEL UTHR SAGE

| Held by: IJH VTI VB VXF VBR CALF MDY IJJ SPMD DFAT

Scroll to Statements

Index	-	P/E	14.31	EPS (ttm)	7.42	Insider Own	4.71%	Shs Outstand	61.62M	Perf Week	-0.60%
Market Cap	6.42B	Forward P/E	4.92	EPS next Y	21.56	Insider Trans	2.45%	Shs Float	57.66M	Perf Month	-1.98%
Enterprise Value	9.27B	PEG	3.42	EPS next Q	-7.42	Inst Own	99.53%	Short Float	10.11%	Perf Quarter	-13.67%
Income	482.20M	P/S	1.58	EPS this Y	-76.35%	Inst Trans	1.13%	Short Ratio	5.11	Perf Half Y	-14.23%
Sales	4.06B	P/B	1.57	EPS next Y	336.26%	ROA	4.22%	Short Interest	5.83M	Perf YTD	-13.83%
Book/sh	67.75	P/C	2.50	EPS next 5Y	4.18%	ROE	12.25%	52W High	148.06 -28.32%	Perf Year	-0.97%
Cash/sh	42.50	P/FCF	4.24	EPS past 3/5Y	- -1.00%	ROIC	5.05%	52W Low	95.49 11.13%	Perf 3Y	-29.61%
Dividend Est.	-	EV/EBITDA	7.38	Sales past 3/5Y	9.56% 13.48%	Gross Margin	73.41%	Volatility	2.44% 2.47%	Perf 5Y	-6.95%
Dividend TTM	-	EV/Sales	2.28	EPS Y/Y TTM	49.58%	Oper. Margin	14.63%	ATR (14)	3.00	Perf 10Y	-41.46%
Dividend Ex-Date	-	Quick Ratio	2.97	Sales Y/Y TTM	5.76%	Profit Margin	11.86%	RSI (14)	43.01	Recom	1.16
Dividend Gr. 3/5Y	- -	Current Ratio	3.38	EPS Q/Q	-549.10%	SMA20	-2.51%	Beta	0.33	Target Price	182.80
Payout	0.00%	Debt/Eq	1.30	Sales Q/Q	-0.46%	SMA50	-2.17%	Rel Volume	0.64	Prev Close	106.90
Employees	2800	LT Debt/Eq	1.29	Earnings	May 06 AMC	SMA200	-10.21%	Avg Volume	1.14M	Price	106.12
IPO	Jun 01, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	-63.93% -8.74%	Trades		Volume	728,509	Change	-0.73%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Upgrade	UBS	Neutral → Buy	$145 → $179
Feb-26-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Feb-13-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$130 → $170
Dec-12-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$140 → $175
Jun-05-24	Initiated	Goldman	Buy	$169
Jan-03-24	Initiated	Robert W. Baird	Outperform	$160
Nov-27-23	Downgrade	UBS	Buy → Neutral	$170 → $135
Sep-29-23	Initiated	Raymond James	Mkt Perform
Jun-12-23	Resumed	Wells Fargo	Equal Weight	$184 → $140
Dec-09-22	Upgrade	Goldman	Neutral → Buy	$192 → $190
Jun-14-22	Initiated	UBS	Buy	$194
Apr-06-22	Downgrade	Goldman	Buy → Neutral	$202 → $196
Nov-19-21	Resumed	Goldman	Buy	$198
Oct-07-21	Resumed	Jefferies	Buy	$172
Oct-05-21	Initiated	Citigroup	Buy	$200
Sep-23-21	Initiated	Needham	Buy	$220
May-19-21	Resumed	JP Morgan	Overweight	$183 → $206
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$186
Feb-05-21	Reiterated	H.C. Wainwright	Buy	$195 → $207
Feb-03-21	Upgrade	Piper Sandler	Neutral → Overweight	$150 → $175

Show Previous Ratings

Jun-27-25 05:22AM	The 5 Most Interesting Analyst Questions From Jazz Pharmaceuticals's Q1 Earnings Call (StockStory)
Jun-11-25 07:59PM	Jazz Pharmaceuticals Releases Unexpected Phase 4 Results Highlighting Xywav (Insider Monkey)
Jun-10-25 07:05AM	Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer (PR Newswire)
Jun-09-25 06:00PM	Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 (PR Newswire)
Jun-05-25 11:30AM	Why Is Jazz (JAZZ) Up 7.9% Since Last Earnings Report? (Zacks)
04:05PM	Loading…
Jun-02-25 04:05PM	Jazz Pharmaceuticals Announces Zepzelca (lurbinectedin) and Atezolizumab (Tecentriq) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer (PR Newswire)
12:35PM	Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025 (PR Newswire)
May-29-25 07:30AM	Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025 (PR Newswire)
May-23-25 06:02AM	Insiders Pour Millions into These 3 Stocks Heres Why They Draw Plaudits Across the Board (TipRanks)
May-21-25 04:30PM	Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences (PR Newswire)
May-19-25 09:53AM	JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook (StockStory)
May-13-25 09:16AM	Unlocking Jazz (JAZZ) International Revenues: Trends, Surprises, and Prospects (Zacks)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-09-25 08:51AM	Pharma Stock Roundup: NVO & JAZZ's Q1 Results, AZN's Pipeline Update (Zacks)
May-08-25 06:36PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
07:20AM	Loading…
07:20AM	Cannabis Stock Tilray Brands Loses 19% in a Month: Time to Sell or Hold? (Zacks)
May-07-25 07:13PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) -8.75%
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
11:00AM	Appeals court reverses-in-part, vacates-in part ruling in Avadel-Jazz fight (TipRanks)
08:33AM	Jazz Pharmaceuticals (JAZZ): Among Billionaire Ray Dalio's Bridgewater's Stock Picks with Huge Upside Potential (Insider Monkey)
03:19AM	Jazz Pharmaceuticals PLC (JAZZ) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
May-06-25 11:06PM	Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript (Seeking Alpha) -5.94%
06:30PM	Here's What Key Metrics Tell Us About Jazz (JAZZ) Q1 Earnings (Zacks)
05:20PM	Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates (Zacks)
04:05PM	Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance (PR Newswire)
09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
May-05-25 09:40AM	Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock (Zacks)
May-02-25 07:41PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
May-01-25 10:01AM	Illumina (ILMN) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-30-25 04:15PM	Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference (PR Newswire)
07:18AM	Loading…
07:18AM	Buy, Sell or Hold JAZZ Stock? Key Tips Ahead of Q1 Earnings (Zacks)
Apr-29-25 09:30PM	Franklin Convertible Securities Fund Q1 2025 Commentary (Seeking Alpha)
10:01AM	Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: Should You Buy? (Zacks)
08:14AM	3 Unconventional Cannabis Stocks to Watch in 2025 (Zacks)
Apr-28-25 05:33PM	Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline (Seeking Alpha)
05:05AM	3 Reasons to Sell JAZZ and 1 Stock to Buy Instead (StockStory)
Apr-25-25 11:27AM	Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer (PR Newswire)
Apr-23-25 04:15PM	Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma (PR Newswire)
11:17AM	Buy 5 High ROE Stocks as Markets Break Tariff-Induced Losing Streak (Zacks)
Apr-22-25 04:15PM	Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 (PR Newswire)
07:21AM	Cardiol Therapeutics Stock: Is Cannabis Potential Priced In? (Zacks)
Apr-21-25 04:05PM	Jazz Pharmaceuticals Completes Acquisition of Chimerix (PR Newswire)
09:22AM	Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria (Zacks)
07:36AM	JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? (Zacks)
Apr-17-25 11:40AM	JAZZ vs. ARGX: Which Stock Is the Better Value Option? (Zacks)
09:40AM	Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term (Zacks)
07:49AM	Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? (Zacks)
05:06AM	Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers (StockStory)
Apr-16-25 11:47AM	Sanofi Advances Mid-to-Late-Stage Pipeline in Respiratory Indications (Zacks)
Apr-15-25 10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks)
09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks)
Apr-14-25 09:51AM	Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe (Zacks)
Apr-11-25 11:49AM	Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate (Zacks)
Apr-10-25 03:30PM	Harbor Mid Cap Value Fund Q4 2024 Commentary (Seeking Alpha) -7.33%
11:50AM	TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why (Zacks)
11:05AM	TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up (Zacks)
08:13AM	Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? (Zacks)
06:20AM	Should John Hancock Multifactor Small Cap ETF (JHSC) Be on Your Investing Radar? (Zacks)
Apr-09-25 03:59PM	Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play Out (Seeking Alpha) +7.10%
08:45AM	JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks)
Apr-08-25 06:56PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Apr-07-25 10:53AM	AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs (Zacks)
10:02AM	5 High ROE Stocks to Buy as Markets Face Tariff Bloodbath (Zacks)
06:20AM	Is John Hancock Multifactor Small Cap ETF (JHSC) a Strong ETF Right Now? (Zacks)
Apr-04-25 01:10PM	AMGN's Uplizna Gets FDA Nod for 2nd Rare Autoimmune Disease Indication (Zacks) -8.92%
Apr-03-25 11:27AM	SNY's Rilzabrutinib Gets FDA's Orphan Drug Tag for Two Rare Diseases (Zacks)
Apr-02-25 11:29AM	AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol (Zacks)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 10:55AM	VRTX Provides Mixed Updates for Type 1 Diabetes Pipeline Candidates (Zacks)
09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Mar-31-25 11:40AM	JAZZ or ARGX: Which Is the Better Value Stock Right Now? (Zacks)
Mar-29-25 04:15PM	Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? (Insider Monkey)
Mar-28-25 09:26AM	BEAM's IND for BEAM-302 in Genetic Disorder Study Gets FDA Clearance (Zacks)
Mar-27-25 11:36AM	NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New Indication (Zacks)
11:30AM	Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? (Zacks)
07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 04:15PM	Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (PR Newswire)
11:51AM	AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint (Zacks)
Mar-25-25 05:39PM	Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts (InsiderMonkey)
Mar-24-25 09:50AM	Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term (Zacks)
04:26AM	Zacks.com featured highlights include MPLX LP, Leidos, Jazz Pharmaceuticals, Fortinet and Pilgrim's Pride (Zacks)
Mar-22-25 04:09PM	TPB, ACB and JAZZ: Three Pot Stocks Flowering With Potential Upside (TipRanks)
Mar-21-25 12:04PM	5 High ROE Stocks to Buy as Markets Dip Despite Rate Cut Hopes (Zacks)
Mar-20-25 01:03PM	3 Promising Biotechs Trading Substantially Under Consensus Analyst Firm Price Targets (SeekingAlpha)
09:38AM	4 Top PEG Stocks Based on GARP Approach to Smart Investing (Zacks)
Mar-19-25 12:14PM	HRMY Down 10.8% in Six Months: How Should You Play the Stock? (Zacks)
09:55AM	Does Jazz (JAZZ) Have the Potential to Rally 38.94% as Wall Street Analysts Expect? (Zacks)
09:02AM	3 Value Stocks Skating on Thin Ice (StockStory)
07:30AM	Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution and Epidiolex (cannabidiol) at American Academy of Neurology Annual Meeting (PR Newswire)
Mar-17-25 11:21AM	Cash In On The Luck Of The Irish With 5 St. Patrick's Day Stocks Near Buy Points (Investor's Business Daily)
07:53AM	Five Irish Stocks Near Buy Points To Add Green To Your Portfolio On St. Patrick's Day (Investor's Business Daily)
Mar-14-25 09:40AM	Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock (Zacks)
Mar-12-25 06:00AM	Bull of the Day: Jazz Pharmaceuticals (JAZZ) (Zacks)
Mar-09-25 06:09PM	Why Chimerix, Inc. (CMRX) Soared Last Week (Insider Monkey)
Mar-05-25 01:03PM	Jazz Pharmaceuticals bids for Chimerix in $935m deal (Pharmaceutical Technology)
07:00AM	Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio (PR Newswire)
06:53AM	Jazz expands in oncology with $935M deal for Chimerix (BioPharma Dive)
Mar-04-25 08:07AM	3 Small-Cap Stocks Skating on Thin Ice (StockStory)
Mar-03-25 06:51PM	Jazz Pharmaceuticals plc (JAZZ): Among the Cash-Rich Mid Cap Stocks to Buy Now (Insider Monkey)
12:20PM	Earnings Estimates Moving Higher for Jazz (JAZZ): Time to Buy? (Zacks)

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COZADD BRUCE C	Chairman & CEO	Jun 03 '25	Sale	110.00	500	55,000	437,973	Jun 04 04:50 PM
COZADD BRUCE C	Chairman & CEO	Jun 02 '25	Sale	107.90	500	53,950	438,473	Jun 04 04:50 PM
COZADD BRUCE C	Officer	Jun 02 '25	Proposed Sale	108.95	1,000	108,950		Jun 02 05:03 PM
Mulligan Seamus	Director	May 09 '25	Buy	98.26	100,000	9,826,120	100,000	May 13 06:51 PM
Mulligan Seamus	Director	May 12 '25	Buy	103.00	1,621	166,962	101,621	May 13 06:51 PM
COZADD BRUCE C	Chairman & CEO	May 01 '25	Sale	116.35	1,000	116,350	439,307	May 05 07:00 PM
COZADD BRUCE C	Chairman & CEO	May 02 '25	Sale	120.00	500	60,000	438,807	May 05 07:00 PM
COZADD BRUCE C	Officer	May 01 '25	Proposed Sale	117.57	1,500	176,350		May 01 04:09 PM
COZADD BRUCE C	Chairman & CEO	Apr 01 '25	Sale	123.75	1,500	185,625	440,307	Apr 03 05:32 PM
COZADD BRUCE C	Officer	Apr 01 '25	Proposed Sale	125.31	2,000	250,625		Apr 01 04:32 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 10 '25	Sale	138.41	2,403	332,605	79,621	Mar 12 02:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 10 '25	Sale	137.81	1,140	157,103	7,012	Mar 11 06:17 PM
Iannone Robert	Officer	Mar 10 '25	Proposed Sale	145.00	1,767	256,215		Mar 10 06:01 PM
Carr Patricia	Officer	Mar 10 '25	Proposed Sale	137.81	1,140	157,103		Mar 10 05:36 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Mar 07 '25	Sale	138.60	7,080	981,298	82,024	Mar 07 06:49 PM
ROBERT IANNONE	Officer	Mar 07 '25	Proposed Sale	138.73	5,466	758,305		Mar 07 05:14 PM
Iannone Robert	Officer	Mar 07 '25	Proposed Sale	142.26	4,017	571,476		Mar 07 05:04 PM
Henderson Mary Elizabeth	Officer	Mar 07 '25	Proposed Sale	139.00	1,295	180,005		Mar 07 03:15 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Option Exercise	113.77	4,813	547,562	12,737	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '25	Sale	144.42	4,813	695,075	8,237	Mar 03 07:21 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 28 '25	Sale	143.29	773	110,767	9,485	Mar 03 07:21 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 27 '25	Sale	144.87	3,800	550,506	33,318	Mar 03 07:18 PM
COZADD BRUCE C	Chairman & CEO	Mar 03 '25	Sale	144.25	6,500	937,625	464,058	Mar 03 07:13 PM
COZADD BRUCE C	Officer	Mar 03 '25	Proposed Sale	144.25	6,500	937,625		Mar 03 04:44 PM
Carr Patricia	Officer	Feb 28 '25	Proposed Sale	143.30	773	110,767		Feb 28 05:43 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	139.00	1,641	228,099		Feb 27 08:05 PM
Carr Patricia	Officer	Feb 27 '25	Proposed Sale	144.42	4,813	695,075		Feb 27 05:04 PM
Patil Neena M	Officer	Feb 27 '25	Proposed Sale	144.87	3,800	550,518		Feb 27 04:56 PM
COZADD BRUCE C	Chairman & CEO	Feb 03 '25	Sale	122.31	1,500	183,465	439,744	Feb 05 05:41 PM
COZADD BRUCE C	Officer	Feb 03 '25	Proposed Sale	122.31	1,500	183,465		Feb 03 05:04 PM
COZADD BRUCE C	Chairman & CEO	Jan 02 '25	Sale	123.43	1,500	185,145	425,525	Jan 06 04:22 PM
COZADD BRUCE C	Officer	Jan 02 '25	Proposed Sale	123.43	1,500	185,145		Jan 02 05:00 PM
COZADD BRUCE C	Chairman & CEO	Dec 02 '24	Sale	121.17	2,000	242,340	427,025	Dec 04 05:24 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 02 '24	Sale	122.49	53	6,492	6,596	Dec 04 05:20 PM
COZADD BRUCE C	Officer	Dec 02 '24	Proposed Sale	121.17	2,000	242,340		Dec 02 06:05 PM
Carr Patricia	Officer	Dec 02 '24	Proposed Sale	122.49	53	6,492		Dec 02 04:20 PM
Patil Neena M	EVP & Chief Legal Officer	Nov 08 '24	Sale	123.41	3,700	456,617	33,048	Nov 13 05:44 PM
Patil Neena M	Officer	Nov 08 '24	Proposed Sale	123.41	3,700	456,632		Nov 08 05:55 PM
COZADD BRUCE C	Chairman & CEO	Nov 01 '24	Sale	110.84	1,000	110,840	428,976	Nov 05 05:00 PM
COZADD BRUCE C	Officer	Nov 01 '24	Proposed Sale	110.84	1,000	110,840		Nov 01 03:19 PM
Henderson Mary Elizabeth	SVP, Technical Operations	Sep 06 '24	Sale	108.30	1,410	152,703	14,531	Sep 11 11:38 AM
Henderson Mary Elizabeth	Officer	Sep 06 '24	Proposed Sale	110.00	2,691	296,010		Sep 05 07:50 PM
Winningham Rick E	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:57 PM
Smith Mark Douglas	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:55 PM
RIEDEL NORBERT G	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:49 PM
ORiordan Anne	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:42 PM
O'Keefe Kenneth W	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:35 PM
McSharry Heather Ann	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:29 PM
Cook Jennifer E.	Director	Aug 06 '24	Proposed Sale	111.00	3,075	341,325		Aug 05 09:19 PM
Sohn Catherine A.	Director	Aug 05 '24	Proposed Sale	111.00	3,075	341,325		Aug 02 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

JAZZ

Jazz Pharmaceuticals plc

Upgrade your FINVIZ experience